FDA's Temple Changes Roles As Part Of CDER Shuffle
Executive Summary
The elevation of FDA's Bob Temple to Deputy Director for Clinical Science within the Center for Drug Evaluation & Research will give the dean of the drug review group broader scope on technical scientific issues, but the most immediate impact of the change will be a withdrawn role on drug promotion and marketing issues